Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
ARID1A Antibody (3611), Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP243566
Description
Ensure accurate, reproducible results in Western Blot
ARID1A Monoclonal specifically detects ARID1A in Human, Mouse samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
ARID1A | |
Monoclonal | |
Unconjugated | |
PBS with No Preservative | |
ARID1A | |
Recombinant protein encompassing a sequence within the C-terminus region of human ARID1A. The exact sequence is proprietary. | |
Protein G purified | |
RUO | |
Primary | |
Human, Mouse | |
Purified |
Western Blot, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
3611 | |
Western Blot 1:500-1:3000, Immunohistochemistry 1:100-1:1000, Immunocytochemistry/Immunofluorescence 1:100-1:1000, Immunohistochemistry-Paraffin 1:100-1:1000 | |
ARID domain-containing protein 1A, AT rich interactive domain 1A (SWI- like), AT rich interactive domain 1A (SWI-like), AT-rich interactive domain-containing protein 1A, B120SWI-like protein, BAF250a, BAF250SWI/SNF complex protein p270, BM029, brain protein 120, BRG1-associated factor 250, BRG1-associated factor 250a, C10rf4, C1orf4SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatinsubfamily F member 1, chromatin remodeling factor p250, hELD, hOSA1, matrix associated, actin dependent regulator of chromatin, Osa homolog 1, OSA1, OSA1 nuclear protein, P270, SMARCF1, subfamily f, member 1 | |
Mouse | |
242 kDa | |
0.1 mL | |
Signal Transduction | |
8289 | |
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction